142890-13-9

Upstream product

• 17342-08-4 (S)-Pyroglutaminol 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 132974-83-5 (5S)-5-[[(tert-butyldiphenylsilyl)oxy]methyl]pyrrolidin-2-one 

Downstream Products

• 142890-21-9 (R)-2-(5-p-toluenesulfonyloxymethylpyrrolidin-2-ylidene)malonic acid diethyl ester 
• 142890-36-6 (S)-2-bis(ethoxycarbonyl)methylidene-5-phenylthiomethylpyrrolidine 
• 142890-20-8 2-[(S)-5-(Toluene-4-sulfonyloxymethyl)-pyrrolidin-2-ylidene]-malonic acid dibenzyl ester 
• 142890-19-5 2-[(S)-5-(Toluene-4-sulfonyloxymethyl)-pyrrolidin-2-ylidene]-malonic acid diethyl ester 
• 142890-26-4 2-((S)-5-Iodomethyl-pyrrolidin-2-ylidene)-malonic acid dibenzyl ester 
• 142890-24-2 2-((S)-5-Bromomethyl-pyrrolidin-2-ylidene)-malonic acid dibenzyl ester 
• 153649-64-0 2-((S)-5-Hydroxymethyl-pyrrolidin-2-ylidene)-malonic acid dibenzyl ester 
• 142890-29-7 (S)-2-(1-Aza-bicyclo[3.1.0]hex-2-ylidene)-malonic acid dibenzyl ester 
• 869287-23-0 {4-[2-(4-fluoro-phenyl)-5-(4-methoxy-benzyloxymethyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl]-pyrimidin-2-yl}-propyl-amine 
• 471844-88-9 2-(4-fluoro-phenyl)-5-(4-methoxy-benzyloxymethyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 
• 926659-97-4 (S)-5-((tert-butyldiphenylsilyloxy)methyl)-2-(4-fluorophenyl)-6,7-dihydro-5Hpyrrolo[1,2-a]imidazole 
• 869287-24-1 [2-(4-fluoro-phenyl)-3-(2-propylamino-pyrimidin-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-5-yl]-methanol 
• 471844-84-5 2-(4-fluoro-phenyl)-5-(4-methoxy-benzyloxymethyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 
• 869287-22-9 5-(tert-butyl-diphenyl-silanyloxymethyl)-4,5-dihydro-3H-pyrrol-2-ylamine 

Relevant academic research and scientific papers

The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold

Imidazole-based structures of p38 inhibitors served as a starting point for the design of JNK3 inhibitors. Construction of a 6,7-dihydro-5H-pyrrolo[1,2-a] imidazole scaffold led to the synthesis of the (S)-enantiomers, which exhibited p38/JNK3 IC50 ratio of up to 10 and were up to 20 times more potent inhibitors of JNK3 than the relevant (R)-enantiomers. The JNK3 inhibitory potency correlated well with inhibition of c-Jun phosphorylation and neuroprotective properties of the compounds in low K+-induced cell death of rat cerebellar granule neurones.

Synthetic studies of carzinophilin. Part 1: Synthesis of 2-methylidene-1-azabicyclo[3.1.0]hexane systems related to carzinophilin

Synthesis of the model compounds of carzinophilin carrying 2-methylidene-1-aza-bicyclo[3.1.0]hexane systems was achieved. Formation of malonylidenes or N-acyl-glycinylidenepyrrolidines was carried out by utilizing Eschenmoser's sulfide contraction or Herdeis's condensation between the 2-methylthio-Δ1-pyrrolone derivatives and ethyl nitroacetate, respectively. The 1-azabicyclo-[3.1.0]hexane systems were constructed by base-promoted aziridine formation.

Synthesis, Chemical Reactivity, and Cytotoxicity of 2-Bis(alkoxycarbonyl)methyliden-1-azabicyclohexane Systems Related to Antitumor Antibiotic Carzinophilin A

Enantiomeric pairs of the title compounds were synthesized starting from (S)- and (R)-pyroglutamic acid.They were found to be susceptible to nucleophilic ring opening of aziridine moieties and to exhibit weak in vitro cytotoxicity.